Pulse Biosciences reports positive 6- and 12-month first-in-human data for nPulse Cardiac Catheter in atrial fibrillation
- Updated feasibility results presented as late-breaking clinical session at Heart Rhythm 2026.
- Data demonstrate high durable procedural success with low serious adverse event rate in atrial fibrillation patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.